Objectives: Emergence and spread of antimicrobial resistance (AMR) in Neisseria gonorrhoeae remain a major global problem and expanded, but valid, AMR surveillance is crucial for public health purposes. The World Health Organization (WHO) Collaborating Centre in Sydney, Australia, continually evaluates N. gonorrhoeae strains used in quality control and assurance aspects of the national, WHO regional and international programmes for AMR surveillance it conducts. Here we phenotypically and genetically characterized the 2008 WHO N. gonorrhoeae reference panel, widely used under existing WHO AMR surveillance protocols.
Introduction
The impact of antimicrobial resistance (AMR) in Neisseria gonorrhoeae on the effective treatment and thus the control of gonorrhoea is of long-standing concern. Recognition of clinical treatment failures of penicillins in widely dispersed jurisdictions shortly after their introduction prompted the World Health Organization (WHO) to develop systems for surveillance of in vitro AMR in N. gonorrhoeae. These surveillance data were used to prepare, and modify as required, standard regimens for the treatment of gonorrhoea, and in epidemiological studies and inter-laboratory data comparisons. An international collaborative Tel: þ46-19-6021520; Fax: þ46-19-127416; E-mail: magnus.unemo@orebroll.se group recommended in 1965 that, in the absence of any prospect of adoption of uniform testing methods, inter-laboratory comparisons of in vitro AMR data should be made through the use of international reference control cultures, and nominated three gonococcal reference strains, WHO III, V and VII, for this purpose. 1 As AMR to the penicillins increased and that to other agents such as spectinomycin and the tetracyclines emerged and spread, a second selection of WHO control strains, WHO A -E, nominated by the then WHO Collaborating Centre in Copenhagen, Denmark, was prepared and released. These control strains ultimately became inadequate as resistance, especially to fluoroquinolones, became widely established. The current WHO Collaborating Centre in Sydney, Australia, has, as part of its terms of reference, undertaken extensive and continuing assessments over many years to evaluate the suitability of numerous different N. gonorrhoeae strains obtained from its own and several other sources for use in the internal quality control and external quality assurance aspects of national, WHO regional and international programmes for surveillance of gonococcal AMR. 2 -5 The evaluations of these strains have included multiple testing of candidate strains as 'unknowns' at multiple sites using different test procedures; assessment of intra-and inter-laboratory reproducibility of results especially in relation to the detection of susceptible and resistant phenotypes; assessment of the durability and viability of candidate strains in field trials and the relevance of the panel to emerging and established patterns of resistance to antimicrobials used for treatment. On the basis of these studies, several panels of WHO control strains have been extensively used and continuously evaluated, especially within Australia (uniform methods), and in the WHO Western Pacific and WHO South East Asian regions (multiple methodologies) and, in response to changing AMR patterns, modified by the WHO Collaborating Centre in Sydney over time.
Regimens for the treatment of gonorrhoea are increasingly being based on oral and/or injectable expanded-spectrum thirdgeneration cephalosporins such as cefixime and ceftriaxone, but concerns have recently been expressed about their continuing effectiveness. 6 -11 This situation, together with the emergence of reduced susceptibility and resistance to azithromycin, has seen calls for renewed and enhanced efforts for the control of gonococcal disease, which include expanded national, international and global AMR surveillance programmes. 8, 10, 11 However, any expansion of current WHO programmes as well as new or other existing surveillance initiatives for public health purposes 3,5,12 -15 for surveillance of resistance to these or other antimicrobials would still require valid comparison of the in vitro AMR data obtained. A group of five international centres, represented in the International Collaboration on Gonococci (http://www.icgngo.org), recently reported that international comparisons of AMR data in N. gonorrhoeae based on comparisons of numeric MIC values were compromised by several factors, even when the same methods were supposedly used. In the absence of any likelihood of a functional uniform methodology emerging soon (or ever), the wider distribution and use of appropriate WHO control strains were again recommended as a means of obtaining the necessary data comparisons for public health purposes by basing these comparisons on the reliable recognition of AMR phenotypes by employing reference cultures, 1, 16 for example, the 2008 N. gonorrhoeae reference panel strains. 8 This present study characterized the 2008 WHO N. gonorrhoeae reference panel phenotypically [antibiograms, auxotypes, serovars and presence of prolyliminopeptidase (PIP) for epidemiological purposes] and genotypically [resistance plasmid types, polymorphisms in divergent genetic resistancemediating loci (n¼ 9) and full-length porB sequencing and N. gonorrhoeae multi-antigen sequence typing (NG-MAST) for molecular epidemiological purposes]. The molecular characterization of resistance mechanisms is becoming increasingly relevant for surveillance of resistance to antimicrobials such as fluoroquinolones, spectinomycin, azithromycin and especially for the expanded-spectrum third-generation cephalosporins, 6,7,17 -19 even though current test criteria remain based on in vitro MIC susceptibility determinations. This current panel of eight WHO N. gonorrhoeae control strains is intended for the internal and external quality assurance and quality control components of gonococcal AMR testing protocols, and is a prerequisite for any global WHO AMR surveillance programme for N. gonorrhoeae. It is also suggested that laboratories using the now superseded WHO A-E reference strains should update these to the current panel. The further rationale and applications for, and uses of, the WHO N. gonorrhoeae control strains and panels are provided in WHO documents elsewhere. 16, 20 Materials and methods , were cultivated and preserved as described previously. 21 
Bacterial strains

Auxotype determination
Auxotyping was performed as described previously. 22 
Serovar determination
Serovar determination using PhadeBact GC Monoclonal Serovar Test (Bactus AB, Stockholm, Sweden) was performed as described previously. 23 
Detection of PIP
PIP production was detected as described previously.
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Antimicrobial susceptibility testing b-Lactamase production was detected using nitrocefin discs, and MICs (mg/L) of 14 antimicrobials were determined using the Etest method (AB Biodisk, Solna, Sweden) as described previously. 25 For the purposes of their phenotypic characterization only, the susceptible, intermediate susceptibility and resistance (S, I and R) categorization, based on the interpretative criteria published by the Swedish Reference Group on Antibiotics (SRGA; www.srga.com) using this method, 25 was also determined. For the antimicrobials where SRGA does not describe any breakpoints (ertapenem, kanamycin, gentamicin and rifampicin), breakpoints from other sources were used (www.bsac.org.uk). 26, 27 In order to reduce the effect of inter-assay variations, for all strains and antimicrobials each determination was performed three times using new bacterial suspensions and the consensus MIC was reported.
Isolation of bacterial DNA
Genomic DNA was isolated using the MagNA Pure LC system (Roche Diagnostics GmbH, Mannheim, Germany), as described previously. 17 Plasmid DNA was extracted using the QIAprep Spin Miniprep Kit (QIAGEN GmbH, Hilden, Germany) according to the manufacturer's instructions. Isolated DNA was stored at 48C prior to PCR amplification.
PCR amplification of genes associated with AMR and molecular epidemiology
The primers, instruments, PCR programmes and reaction mixtures used in the amplification of each gene are summarized in Table 1 . All PCR products were stored at 48C prior to purification.
PCR product purification
All PCR products were purified using the High Pure PCR Product Purification Kit (Roche Diagnostics GmbH) in accordance with the instructions of the manufacturer.
DNA sequencing and sequence analysis
All cycle sequencing PCRs were performed using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) on a GeneAmp 2720 Thermal Cycler (Applied Biosystems), according to the manufacturer's instructions. The primers used are described in Table 2 . The purification of the cycle sequencing extension products and the sequence determination on an ABI PRISM TM 3100 Genetic Analyzer (Applied Biosystems) were performed as documented previously. 23, 36 The resulting chromatograms were corrected and assembled using the ChromasPro (version 1.34) software (Technelysium Pty Ltd, Tewantin, Australia). Sequence alignments were performed using BioEdit Sequence Alignment Editor (version 7.0.9.0) software (Ibis Biosciences, Carlsbad, CA, USA). Determination of NG-MAST 34 sequence types (STs) was performed using partial tbpB and porB sequences as described previously. 23 
Results
The results of the phenotypic and genetic characterization are summarized in Tables 3 and 4 .
Phenotypic characterization
Four (50%) of the strains were of proline-requiring auxotype and the remaining four were non-requiring. The strains represented both serogroups WI (PorB1a; n ¼ 3) and WII/III (PorB1b; n ¼ 5), and in total, five different serovars [Arst (n ¼3), Bpyust (n ¼ 2) and one strain each of serovar Brpyust, Boys and Bopt]. Two of the strains (WHO G and N) were PIP-negative (Table 3) . b-Lactamase production was detected in three of the strains (WHO M, N and O). For the purposes of their phenotypic characterization only, the SIR categorization and consensus MICs for each antimicrobial and strain, as well as the range of detected MICs for all strains, as determined by the single method used, are presented in Table 4 , and are also referred to further on.
Genetic characterization
Of the b-lactamase (TEM-1)-producing strains (n¼ 3), two (WHO M and O; penicillin G, MIC 8 and .32 mg/L) carried plasmids of the African type and one (WHO N; penicillin G, MIC 8 mg/L) of the Asian type. 29 The tet(M)-carrying conjugative plasmids, which encode a ribosome-protecting protein, identified in two of the strains (WHO G and N; tetracycline, MICs 16 and 32 mg/L), were of the Dutch type. 28 Regarding penA, one of the strains (WHO F) contained a wild-type allele ( penicillin G, MIC 0.032 mg/L), one a mosaic allele (WHO K; penicillin G, cefixime and ceftriaxone MICs 2, 0.5 and 0.064 mg/L, respectively) and six displayed the insertion of one codon causing a D345a alteration in penicillin-binding protein 2 (PBP 2), in conjunction with four to six characteristic additional amino acid alterations in the C-terminal transpeptidase region of the protein. WHO L also contained an A501V mutation in penA. Three strains (WHO F, L and N) contained a wild-type mtrR promoter region sequence. The remaining strains (n ¼ 5) displayed a deletion of a single nucleotide (A; n ¼ 4) or an A!C substitution (n ¼ 1) in the 13 bp inverted repeat of the promoter sequence. Three of the strains displayed wild-type mtrR coding region sequences. However, three strains (WHO K, L and M) displayed a G45!D alteration and the remaining two strains (WHO N and P) an insertion or deletion of a single nucleotide causing a frame-shift, subsequent premature stop codon and truncated peptide. Concerning the penB alterations, all the PorB1b strains (n ¼ 5) displayed the A121!D alteration and four of them contained also the G120!K alteration, which mediate decreased permeability of the porin PorB1b. Two of the strains (WHO F and P) had wild-type ponA sequences and the remaining six carried mutations ( ponA1 allele), causing the L421!P alteration in PBP 1. With respect to fluoroquinolones, three of the strains (ciprofloxacin, MIC 0.004 -0.008 mg/L) contained wild-type gyrA, parC and parE quinolone resistancedetermining region (QRDR) sequences. Regarding gyrA and parC, one strain displayed only a GyrA S91!F mutation (WHO G; ciprofloxacin, MIC 0.125 mg/L), one a GyrA S91!F and a GyrA D95!G mutation (WHO M; ciprofloxacin, MIC 2 mg/L) and the remaining ciprofloxacin-resistant strains (WHO K, L and N) contained a GyrA S91!F mutation, a GyrA D95!G/N mutation and one or two amino acid alterations in ParC codons 86 -88 (ciprofloxacin, MIC 4 to .32 mg/L). In addition, two strains (WHO G and N) displayed a G410!V substitution in parE. One strain (WHO O) displayed a C1192!T nucleotide transition in the 16S rRNA gene (C1192!U in the transcribed 16S rRNA; spectinomycin, MIC .1024 mg/L). Concerning rpoB, five strains had a wild-type allele and the three remaining (WHO M, N and P) had an H552!N mutation (rifampicin, MIC .32 mg/L) ( Table 4 ). The strains displayed eight different porB alleles as well as eight divergent NG-MAST STs, of which three have not previously been described (Table 3) . 
Discussion
This study describes the relevant phenotypic and genetic characteristics of the eight WHO N. gonorrhoeae strains comprising the 2008 WHO reference panel. These strains fulfil the necessary prerequisites for use in global quality assurance and quality control aspects of gonococcal AMR testing under existing WHO protocols. Details of the basis of this WHO approach and the rationale and applications for, and use of, these strains are set out elsewhere. 16, 20 The 2008 WHO panel strains represent the important susceptible and resistant phenotypes and the range of resistances currently seen for the antimicrobials recommended in different guidelines and/or used in the gonorrhoea treatment globally. It is emphasized that the consensus MIC values shown (Table 4) were determined using one specific method 25 only and were included for illustrative purposes. The MIC values for these strains may be different in other test systems based on other methodologies; 16 however, the resistance phenotypes displayed should be consistent between test methods. When these methods are reliably performed, they can be applied in AMR surveillance for public health purposes on the basis of the resistance phenotype determination only. 16, 20 If there are inconsistencies between the nominated resistance phenotypes and that obtained using a particular method, close attention should first be paid to the quality control procedures applicable to the test method concerned. Further information, if required, may be obtained from the WHO AMR Surveillance Standards. 20 The exact MICs obtained for the 2008 WHO strains for kanamycin, gentamicin, cefixime, ceftriaxone and ertapenem are also shown in Table 4 . However, for these antimicrobials, no nominated resistance phenotypes (or genotypes) were included because, at present, sufficient and reliable clinical/laboratory correlates are not available. Nevertheless, kanamycin and gentamicin have been used extensively to treat gonorrhoea in some settings, for example, Indonesia and Malawi, 42, 43 and gentamicin, in single use or in combination therapy, and ertapenem have been proposed for possible use in this disease as further resistance to established antimicrobial agents increases or availability of others reduces. 10, 44 Rifampicin has been used in, for example, Indonesia and resistance has been emerging. 43 A spectrum of relevant additional phenotypic markers (auxotypes, serovars and presence of PIP for epidemiological purposes) was also determined.
The presently known genetic alterations, acting singly or collaboratively, that mediate the AMR patterns and genotypic epidemiological markers (full-length porB sequencing and NG-MAST) present in the different resistant phenotypes were also comprehensively detailed (Table 4 ). The documentation of the genetic determinants mediating the AMR to most antimicrobials in the 2008 WHO panel strains is of increasing importance. Determination of AMR phenotypes by isolate-based methods will remain a mainstay of AMR surveillance programmes for gonococcal AMR testing in the immediate future. However, already a combination of isolate-based examination for resistance and molecular-based determination of the mechanisms of resistance has been proposed for the detection of resistance to the oral third-generation cephalosporins. 6 Further, the feasibility of using molecular methods for detecting particular molecular resistance determinants in non-viable gonococci has been proposed (F. Vernel-Pauliac, T. S. Hogan, J. W. Tapsall, M. S. Goarant, unpublished results) to assist in AMR surveillance in situations in which maintaining gonococci for AMR testing is difficult. 45 Additionally, the combined introduction and increasing use of nucleic acid amplification assays in developed countries and that of syndromic, as opposed to aetiologically, based diagnosis in resource-poor settings have resulted in a sharp decline in the number of isolates available for conventional AMR testing and the need for exploration of molecular-based approaches to AMR surveillance. Although there are significant problems regarding the application of current molecular assays to AMR surveillance, it is reasonable to clearly document the currently known genetic changes associated with the resistances present in the WHO reference strains in the expectation that they may be of help in new approaches to AMR surveillance.
The genetic determinants mediating the AMR in the WHO strains were wide ranging, in keeping with the requirements for a reference panel. The resistance to penicillins was plasmidmediated in three strains (WHO M, N and O). In four strains, however, the intermediate susceptibility (WHO G and P) or resistance (WHO K and L) was chromosomally mediated due to the presence of the penA mosaic allele (WHO K) or the penA allele with D345a insertion (WHO G, L and P), the initial and most important mechanism for chromosomally mediated resistance to penicillins. 7, 30, 32, 40, 41 Other genetic AMR determinants that function in a stepwise, specific order when present were also determined. For example, mutations in the mtrR promoter or coding sequence, and penB and ponA1 substitutions, which cumulatively increase the penicillin and tetracycline (mtrR and penB) MICs, 7, 32, 46 were detected. mtrR mutations can increase the expression of the MtrCDE efflux pump and consequently confer resistance to many hydrophobic agents, for example, macrolides, as well as some hydrophilic antimicrobials, e.g. penicillins and tetracyclines. Four of the WHO strains (WHO G, K, M and O) displayed the previously described deletion of a single nucleotide (A) in the 13 bp inverted repeat in the promoter region of Resistance phenotypes based on minimum inhibitory concentration (MIC, mg/L) using Etest. The range of the MICs for each antimicrobial and the different strains are given in parenthesis. Note that the consensus MICs shown should be used and interpreted with caution because these were derived using one specific method only and, accordingly, may differ using other methods. However, the identified resistance phenotypes (SIR categorization) should be consistent between different methods. mtrR 7, 30, 31, 47 and three strains displayed the G45!D mutation that is important mainly if the dominant 'A deletion' in the promoter sequence is not present (WHO L). 7, 47 The mtrR coding and promoter region mutations in WHO P (Table 3 ) seem to be rare but have been previously described in azithromycin-resistant N. gonorrhoeae.
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The penA mosaic allele most notably, but also some of the penA D345a alleles, together with at least mtrR and penB have been previously shown to be associated with reduced susceptibility to expanded-spectrum third-generation cephalosporins, for example, cefixime and ceftriaxone, that are currently the recommended first-line treatment of gonorrhoea in most countries. 7, 30, 38, 41, 49 WHO K (penA mosaic allele, variant X 38 ) also contained the I312M, V316T and G545S mutations proposed to be important for reduced susceptibility to this group of antimicrobials. 39 WHO L (penA D345a allele, variant VII 38 ) contained the A501V mutation suggested by some to also contribute to reduced susceptibility to this group of antimicrobials. 40, 41 All the specific gyrA and parC QRDR mutations identified in the present study (Table 4) have been previously described as being of relevance to the accumulation of sequential QRDR changes, resulting in increased MICs of fluoroquinolones in N. gonorrhoeae. 17,23,30,50 -52 These QRDR changes initially involve specific gyrA mutations encoding alterations in subunit A of DNA gyrase, followed by specific parC mutations encoding alterations in subunit C of topoisomerase IV. The importance of the, to our knowledge, not previously described ParE G410!V alteration (WHO G and N strains), as well as overall ParE (encoding subunit E of topoisomerase IV) alterations for increased MICs of fluoroquinolones in clinical isolates, is most likely of limited microbiological and clinical relevance. 51, 52 All the three rifampicin-resistant (MIC .32 mg/L) reference strains (WHO M, N and P) contained an H552!N mutation in rpoB that encodes RNA polymerase subunit B. This RpoB alteration has been previously correlated to rifampicin resistance in Neisseria meningitidis 53 and most probably is also a main mechanism for rifampicin resistance in N. gonorrhoeae.
The single spectinomycin-resistant (MIC .1024 mg/L) strain (WHO O) displayed a C1192!T nucleotide transition in the 16S rRNA gene (C1192!U in the transcribed 16S rRNA). This single nucleotide polymorphism has been previously associated with spectinomycin resistance in N. gonorrhoeae, as well as in other bacterial species. 54 Inevitably, a few previously identified genetic AMR markers were not examined, such as mutations in chromosomal rpsJ-encoding ribosomal protein S10 that, such as mtrR mutations and penB, can increase the MICs of tetracyclines, 55 or 23S rRNA gene mutations, 56 the macrolide -lincosamide -streptogramin B resistance erm genes encoding 23S rRNA methylases 57 and mef(A) efflux 57 that, such as mtrR mutations, can cause resistance to macrolides. This was mainly because this was not considered essential and these antimicrobials, as well as, for example, chloramphenicol that was also not examined, are no longer recommended for the treatment of gonorrhoea.
In conclusion, in the present study, the 2008 WHO N. gonorrhoeae reference strain panel was extensively characterized both phenotypically and genetically. This characterization was crucial to anticipate the proposed expansion of AMR surveillance in N. gonorrhoeae in national and international programmes. Not only will this panel be widely available through WHO sources for quality assurance and quality control aspects of current testing protocols, it will allow valid comparison of AMR data derived by divergent methods. The panel will also form a basis for controls for possible future molecular assays for AMR detection. Procedures are also in place to allow timely inclusion of additional WHO reference strains if additional resistant phenotypes and/or genotypes emerge or the need for additional studies on these or other WHO strains arises. The emerging resistance to oral cephalosporins 6, 9 and also to azithromycin together with the different doses and drug formulations proposed for this agent suggests that the in vitro criteria for 'resistance' for these two groups of drugs may be candidates for revision in the near future and these processes are currently in train.
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